Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases
Article (Published version)
Metadata
Show full item recordAbstract
The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ.
Keywords:
Biomarker / Carcinogenesis / Endocrine-related cancers / Estrogen Receptor Beta / Isoforms / Metastases / Methylation / Promoters / Tumor-suppressorSource:
International Journal of Molecular Sciences, 2021, 22, 4, 1656-Funding / projects:
Note:
- Special Issue "Biomarkers in Hematological and Oncological Malignancies: Identification, Validation and Involvement in Molecular Pathways"
DOI: 10.3390/ijms22041656
ISSN: 1422-0067
PubMed: 33562134
WoS: 000623881500001
Scopus: 2-s2.0-85100504125
Institution/Community
VinčaTY - JOUR AU - Božović, Ana M. AU - Mandušić, Vesna AU - Todorović, Lidija AU - Krajnović, Milena M. PY - 2021 UR - https://vinar.vin.bg.ac.rs/handle/123456789/9560 AB - The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ. T2 - International Journal of Molecular Sciences T1 - Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases VL - 22 IS - 4 SP - 1656 DO - 10.3390/ijms22041656 ER -
@article{ author = "Božović, Ana M. and Mandušić, Vesna and Todorović, Lidija and Krajnović, Milena M.", year = "2021", abstract = "The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ.", journal = "International Journal of Molecular Sciences", title = "Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases", volume = "22", number = "4", pages = "1656", doi = "10.3390/ijms22041656" }
Božović, A. M., Mandušić, V., Todorović, L.,& Krajnović, M. M.. (2021). Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases. in International Journal of Molecular Sciences, 22(4), 1656. https://doi.org/10.3390/ijms22041656
Božović AM, Mandušić V, Todorović L, Krajnović MM. Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases. in International Journal of Molecular Sciences. 2021;22(4):1656. doi:10.3390/ijms22041656 .
Božović, Ana M., Mandušić, Vesna, Todorović, Lidija, Krajnović, Milena M., "Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases" in International Journal of Molecular Sciences, 22, no. 4 (2021):1656, https://doi.org/10.3390/ijms22041656 . .